LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.
-
Filed today
-
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there - you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings -
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
The company released its latest financial results and plans to raise ₹68,00,00,000 to buy 60% of Meyonex Pharmaceuticals.
🤖 AI Summary
Board approved unaudited Standalone and Consolidated Financial Results for Q2 FY27 and half-year ended September 30, 2026.
Approved in-principle proposal to raise up to ₹68,00,00,000 for 60% acquisition of Meyonex Pharmaceuticals Limited.
Fundraising may occur via preferential issue, rights issue, or other modes; final terms to be decided subsequently.
Changed Registrar & Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd.
Noted no deviation in the utilization of proceeds from the previous Rights Issue offer document.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Fundraising Amount Approved
₹68,00,00,000
Acquisition Stake
60%
Trade Receivables (30 Sep 2026)
698.43 Lacs
Trade Receivables (31 Mar 2026)
817.86 Lacs
Cash and Cash Equivalents (30 Sep 2026)
69.95 Lacs
Cash and Cash Equivalents (31 Mar 2026)
121.10 Lacs
🏢 How This Affects the Company
📈
Business Impact
The proposed acquisition of a 60% stake in Meyonex Pharmaceuticals Limited could expand Tavexia Lifecare's business presence in the pharmaceutical sector. This follows the company's prior approval for the acquisition on October 7, 2026.
💰
Financial Impact
The approved fund-raising of up to ₹68,00,00,000 aims to finance the acquisition, potentially altering the company's capital structure depending on the chosen mode (preferential issue, rights issue, or other securities).
⚙️
Operational Impact
The change in Registrar & Transfer Agent to Skyline Financial Services Pvt. Ltd. suggests an operational shift aimed at enhancing shareholder services and administrative efficiency with a more technologically advanced framework.
⚠️
Risk Impact
The fund-raising proposal involves various securities issuance modes, which will introduce specific financial risks and requirements depending on the final structure approved by the board.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this filing.
👤
Who Is Affected
Existing shareholders may be affected by the future fund-raising, which could involve a rights issue or preferential issue of securities, potentially impacting shareholding dilution or offering participation opportunities.
🔍
Management Signal
The decision to raise ₹68,00,00,000 for a 60% acquisition signals management's intent for inorganic growth and expansion into the pharmaceutical sector, alongside a focus on administrative efficiency via RTA change.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Announcement of final terms and mode for the ₹68,00,00,000 fund-raising.
Disclosure of specific details regarding the 60% acquisition of Meyonex Pharmaceuticals.
Intimation of the effective date for the change of Registrar & Transfer Agent to Skyline Financial Services.
MEDIUM RISKThe fund-raising for acquisition involves execution risks related to terms, valuation, and integration of the acquired entity.
💡 Investor Takeaway
Tavexia Lifecare's board approved Q2 FY27 results and an in-principle fund-raising of up to ₹68,00,00,000 to acquire a 60% stake in Meyonex Pharmaceuticals Limited. This strategic move aims for business expansion, with the mode of fundraising to be determined later. The company also confirmed no deviation in prior Rights Issue fund utilization.
⚖️ Strengths & Concerns
✅ Positives
In-principle approval to raise up to ₹68,00,00,000 for a significant 60% acquisition, indicating strategic growth initiatives.
Statement of no deviation or variation in the use of proceeds from the Rights Issue, ensuring fund utilization as planned.
⚠️ Concerns
Unaudited Balance Sheet as at 30th September 2026 shows Trade receivables decreased to 698.43 Lacs from 817.86 Lacs at 31st March 2026.
Unaudited Balance Sheet shows Cash and cash equivalents decreased to 69.95 Lacs from 121.10 Lacs at 31st March 2026.
📅 Company Track Record
Tavexia Lifecare (formerly Sattva Sukun Lifecare) had previously approved ₹68,00,00,000 fund-raising for a 60% acquisition of Meyonex Pharmaceuticals on October 7, 2026. The company also confirmed the use of Rs./- 191601248.00 Rights Issue funds without deviation in its Q1 FY27 results filed on August 4, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was the key decision regarding fund-raising by Tavexia Lifecare?
The board approved in-principle a proposal to raise funds up to ₹68,00,00,000 to finance the proposed 60% acquisition of Meyonex Pharmaceuticals Limited.
What is the purpose of the approved fund-raising by Tavexia Lifecare?
The funds are intended to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an acquisition previously approved on October 7, 2026.
Which quarter's financial results did Tavexia Lifecare's board approve?
The board approved the Un-Audited Financial Results (Standalone and Consolidated) for the Quarter and half year ended September 30, 2026, which corresponds to Q2 FY27.
What was Tavexia Lifecare's Trade Receivables as of September 30, 2026?
Tavexia Lifecare's Trade Receivables stood at 698.43 Lacs as of September 30, 2026, compared to 817.86 Lacs as of March 31, 2026.
Did Tavexia Lifecare change its Registrar & Transfer Agent (RTA)?
Yes, the board approved the change of Registrar & Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd.
Questions based on this BSE filing only. For information purposes.
All BSE filings we have analysed for Tavexia Lifecare Ltd.
You've read one filing
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again - explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.